Skip to main content

Table 5 Factors associated with unsuccessful treatment outcomes among new pulmonary smear-negative tuberculosis patients in Anqing, China, 2005–2013 (n = 8156)

From: Treatment outcomes and factors affecting unsuccessful outcome among new pulmonary smear positive and negative tuberculosis patients in Anqing, China: a retrospective study

Variables

Total (n = 8156)

Unsuccessful outcomes

Univariate analysis

Multivariate analysis

OR (95% CI)

P

OR (95% CI)

P

Sex

Female

2266 (27.78)

112 (4.94)

1

   

Male

5890 (72.22)

296 (5.03)

1.02 (0.81, 1.27)

0.88

  

Age

15~ 24

1237 (15.17)

36 (2.91)

1

 

1

 

25~ 34

714 (8.75)

28 (3.92)

1.36 (0.82, 2.25)

0.23

1.34 (0.73, 2.47)

0.34

35~ 44

1189 (14.58)

43 (3.62)

1.25 (0.80, 1.96)

0.33

1.22(0.69, 2.16)

0.50

45~ 54

1275 (15.63)

65 (5.10)

1.79 (1.18, 2.71)

< 0.001

1.79 (1.04, 3.09)

0.04

55~ 64

1744 (21.38)

87 (4.99)

1.75 (1.18, 2.60)

< 0.001

1.59 (0.93, 2.74)

0.09

≥65

1997 (24.49)

149 (7.46)

2.69 (1.86, 3.90)

< 0.001

2.57 (1.52, 4.35)

< 0.001

Ethnicity

Han

8141 (99.82)

407 (5.00)

0.74 (0.10, 5.62)

0.54

  

Other

15 (0.18)

1 (6.67)

1

   

Occupation

Student

607 (7.44)

19 (3.13)

1

   

Official staff

166 (2.04)

12 (7.23)

2.41 (1.15, 5.08)

0.02

  

Service

160 (1.96)

6 (3.75)

1.21 (0.47, 3.07)

0.69

  

Worker

683 (8.37)

28 (4.10)

1.32 (0.73, 2.39)

0.36

  

Farmer

5940 (72.83)

321 (5.40)

1.77 (1.10, 2.83)

0.02

  

Retired staff

172 (2.11)

13 (7.56)

2.53 (1.22, 5.23)

0.01

  

Unemployment

140 (1.72)

4 (2.86)

0.91 (0.31, 2.72)

0.87

  

Other

388 (3.53)

5 (1.74)

0.55 (0.20, 1.48)

0.23

  

Way of discovering patients

Health examination

165 (2.02)

5 (3.03)

1

   

Contact examination

40 (0.49)

2 (5.00)

1.68 (0.32, 9.01)

0.54

  

Clinic visit due to symptoms

3548 (43.50)

175 (4.93)

1.66 (0.67, 4.10)

0.27

  

Recommended due to symptoms

30 (0.37)

1 (3.33)

1.10 (0.12, 9.79)

0.93

  

Referral

3793 (46.51)

197 (5.19)

1.75 (0.71, 4.32)

0.22

  

Tracing

559 (6.85)

27 (4.83)

1.62 (0.62, 4.29)

0.33

  

Other

21 (0.26)

1 (4.76)

1.60 (0.18, 14.39)

0.68

  

Treatment management models

Self-medication

30 (0.37)

4 (13.33)

2.84 (0.96, 8.41)

0.06

2.95 (0.98, 8.90)

0.055

Full-course supervision

1049 (12.86)

54 (5.15)

1

 

1

 

Full-course management

513 (6.29)

59(11.50)

2.40 (1.63, 3.52)

< 0.001

2.54 (1.70, 3.81)

< 0.001

Supervision in intensive phase

6564 (80.48)

291 (4.43)

0.86 (0.63, 1.15)

0.30

0.95 (0.70, 1.30)

0.76

X-Ray

Normal

122 (1.50)

0

< 0.01 (< 0.01, > 999.99)

0.96

Abnormal

8000 (98.09)

402 (5.03)

1

 

1

 

Unchecked

34 (0.42)

6 (17.65)

4.00(1.67–10.00)

0.002

3.77 (1.50, 9.45)

0.005

Cavity

Yes

683 (8.37)

32 (4.69)

0.93 (0.64, 1.34)

0.69

  

No

7473 (91.63)

376 (5.03)

1

   

Miliary shadow

Yes

70 (0.86)

8 (11.43)

2.48 (1.18, 5.21)

0.02

2.43 (1.12, 5.25)

0.02

No

8086 (99.14)

400 (4.95)

1

 

1

 

Regimen

Regimen 1a

5111 (62.67)

278 (5.44)

1

   

Regimen 2b

3045 (37.33)

130 (4.27)

0.78 (0.63, 0.96)

0.02

  

Total delay

≤13

2047 (25.10)

94 (4.59)

1

 

1

 

13~ 27

2054 (25.18)

80 (3.89)

0.84 (0.62, 1.14)

0.27

0.84 (0.62, 1.14)

0.27

27~ 51

2046 (25.09)

100 (4.89)

1.07 (0.80, 1.43)

0.66

1.05(0.78, 1.41)

0.74

> 51

2009 (24.63)

134 (6.67)

1.49 (1.13, 1.95)

0.004

1.40 (1.06, 1.85)

0.019

  1. a2H3R3Z3E3/4H3R3. R = rifampicin; H = isoniazid; Z = pyrazinamide; E = ethambutol. It means once once-every-other-day HRZE for 2 months followed by 4 months of once-every-other-day HR
  2. b2HRZE/4HR. It means daily HRZE for 2 months followed by 4 months of daily HR